Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pharmacogenomic predictor of long-term residual chemotherapy-induced peripheral neuropathy in ovarian cancer survivors: A substudy of the GINECO Vivrovaire study.
Zenatri M, Perennec T, Michon C, Gernier F, Grellard JM, Piloquet FX, Dubot-Poitelon C, Kalbacher E, Tredan O, Augereau P, Pautier P, Fey L, Joly F, Frenel JS. Zenatri M, et al. Among authors: dubot poitelon c. Gynecol Oncol. 2024 May 21;187:139-144. doi: 10.1016/j.ygyno.2024.04.021. Online ahead of print. Gynecol Oncol. 2024. PMID: 38776631
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group.
Freyer G, Floquet A, Tredan O, Carrot A, Langlois-Jacques C, Lopez J, Selle F, Abdeddaim C, Leary A, Dubot-Poitelon C, Fabbro M, Gladieff L, Lamuraglia M. Freyer G, et al. Among authors: dubot poitelon c. Nat Commun. 2024 Mar 5;15(1):1985. doi: 10.1038/s41467-024-45974-w. Nat Commun. 2024. PMID: 38443333 Free PMC article. Clinical Trial.
Impact of web application support versus standard management on adherence with adjuvant hormone therapy in patients treated for breast cancer: the WEBAPPAC study.
Gernier F, Grellard JM, Dupont C, Castel H, Fernette M, Lahaye F, Charles RM, Leroux T, Ory C, Faveyrial A, Morel A, Emile G, Levy C, Segura C, Allouache D, Johnson A, Geffrelot J, Gunzer K, Lelaidier A, Girault G, Dubot-Poitelon C, San C, Lequesne J, Clarisse B. Gernier F, et al. Among authors: dubot poitelon c. BMC Cancer. 2023 Aug 9;23(1):736. doi: 10.1186/s12885-023-11242-1. BMC Cancer. 2023. PMID: 37559004 Free PMC article. Clinical Trial.
Pretreatment neutrophil to lymphocyte ratio as prognostic factor in metastatic breast cancer treated with cyclin dependent kinase 4/6 inhibitors.
Rottier P, Emile G, Johnson A, Levy C, Allouache D, Hrab I, Segura C, Morel A, Villemin M, Dubot-Poitelon C, Boismoreau L, Cherifi F, Lequesne J, Da Silva A. Rottier P, et al. Among authors: dubot poitelon c. Front Oncol. 2023 Jan 19;12:1105587. doi: 10.3389/fonc.2022.1105587. eCollection 2022. Front Oncol. 2023. PMID: 36741710 Free PMC article.
HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer.
Cherifi F, Da Silva A, Johnson A, Blanc-Fournier C, Abramovici O, Broyelle A, Levy C, Allouache D, Hrab I, Segura C, Morel A, Villemin M, Boscher C, Dubot-Poitelon C, Rottier P, Lequesne J, Emile G. Cherifi F, et al. Among authors: dubot poitelon c. BMC Cancer. 2022 Oct 20;22(1):1081. doi: 10.1186/s12885-022-10163-9. BMC Cancer. 2022. PMID: 36266623 Free PMC article.